QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-initiates-coverage-on-adverum-biotechnologies-with-outperform-rating-announces-price-target-of-25

Oppenheimer analyst Francois Brisebois initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Outperform rating ...

 truist-securities-maintains-buy-on-adverum-biotechnologies-maintains-60-price-target

Truist Securities analyst Joon Lee maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $60 price target.

 hc-wainwright--co-reiterates-buy-on-adverum-biotechnologies-maintains-30-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

 adverum-biotechnologies-q1-2024-adj-eps-150-misses-140-estimate

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimat...

 hc-wainwright--co-initiates-coverage-on-adverum-biotechnologies-with-buy-rating-announces-price-target-of-30

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy rati...

 mizuho-maintains-buy-on-adverum-biotechnologies-lowers-price-target-to-22

Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and lowers the price target from...

 adverum-biotechnologies-to-present-luna-26-week-phase-2-interim-analysis-at-the-asrs-annual-scientific-meeting

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of c...

 why-lifecore-biomedical-shares-are-trading-lower-by-around-32-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it con...

 chardan-capital-reiterates-buy-on-adverum-biotechnologies-maintains-4-price-target

Chardan Capital analyst Daniil Gataulin reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $4 price t...

 rbc-capital-maintains-sector-perform-on-adverum-biotechnologies-lowers-price-target-to-2

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Sector Perform and lowers the price tar...

 adverum-biotechnologies-announces-1-for-10-reverse-stock-split-to-be-effective-march-21-202

Approval of 1-for-10 reverse stock split: On March 8, the Board of Directors approved a 1-for-10 reverse stock split of the Com...

 adverum-biotechnologies-q4-eps-023-beats-034-estimate

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate ...

 why-is-blindness-focused-adverum-biotechnologies-stock-trading-lower-today

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and s...

 adverum-biotechnologies-announced-preliminary-safety-and-efficacy-data-from-the-ongoing-luna-phase-2-trial-of-ixoberogene-soroparvovec-in-patients-with-wet-age-related-macular-degeneration

Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including tr...

 mizuho-maintains-buy-on-adverum-biotechnologies-raises-price-target-to-4

Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and raises the price target from...

 why-air-products-and-chemicals-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-th...